Drug Profile
SB 207448
Latest Information Update: 09 Dec 1999
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Antiplatelets; Vascular disorder therapies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 09 Dec 1999 No-Development-Reported for Thrombosis in USA (Unknown route)
- 05 Oct 1998 Preclinical development for Thrombosis in USA (Unknown route)
- 22 Sep 1998 No-Development-Reported for Thrombosis in USA (Unknown route)